Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cabaletta Bio ( (CABA) ) has shared an announcement.
On September 3, 2025, Cabaletta Bio announced an updated corporate presentation detailing its progress in developing rese-cel, a targeted cellular therapy for autoimmune diseases. The company is conducting Phase 1/2 clinical trials across six indications, with a biologics license application for myositis expected in 2027. The trials have shown promising safety and efficacy data, with most patients experiencing transformative clinical responses.
The most recent analyst rating on (CABA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cabaletta Bio stock, see the CABA Stock Forecast page.
Spark’s Take on CABA Stock
According to Spark, TipRanks’ AI Analyst, CABA is a Underperform.
Cabaletta Bio’s overall score is low primarily due to its financial performance, marked by no revenue and increasing losses. The technical analysis indicates a bearish trend, further impacting the score. However, the recent positive clinical trial data provides a glimmer of hope, slightly improving future outlook. Despite this, the stock’s valuation remains a concern, making it a risky investment at this stage.
To see Spark’s full report on CABA stock, click here.
More about Cabaletta Bio
Cabaletta Bio, Inc. operates in the biotechnology industry, focusing on developing targeted cellular therapies for autoimmune diseases. The company is advancing its product candidate, rese-cel, which targets CD19 for autoimmunity and is conducting multiple clinical trials across various indications.
Average Trading Volume: 1,830,237
Technical Sentiment Signal: Sell
Current Market Cap: $132.6M
For a thorough assessment of CABA stock, go to TipRanks’ Stock Analysis page.